

Edgar Filing: ORASURE TECHNOLOGIES INC - Form 8-K

ORASURE TECHNOLOGIES INC

Form 8-K

May 13, 2002

SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K  
CURRENT REPORT

PURSUANT TO SECTION 13 OR 15 (d)  
OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): May 13, 2002

OraSure Technologies, Inc.  
-----

(Exact name of issuer as specified in charter)

|                              |             |                  |
|------------------------------|-------------|------------------|
| DELAWARE                     | 1-10492     | 36-4370966       |
| (State or Other Jurisdiction | (Commission | (I.R.S. Employer |
| of Incorporation or          | file        | Identification   |
| Organization)                | number)     | Number)          |

150 Webster Street  
Bethlehem, Pennsylvania 18015  
(Address of principal executive offices)

(610) 882-1820  
(Registrant's telephone number, including area code)

Item 5 - Other Events.

OraSure Technologies, Inc. (the "Company") issued a press release on May 13, 2002, announcing receipt of notification from the U.S. Food and Drug Administration that the OraQuick(R) Rapid HIV-1 Antibody Test is approvable, subject to the Company meeting certain conditions. A copy of the press release is attached to this Report as Exhibit 99 and is incorporated herein by reference.

Item 7. - Financial Statements and Exhibits.

(c) Exhibits.

Exhibits are listed on the attached exhibit index following the signature page of this Report.

## Edgar Filing: ORASURE TECHNOLOGIES INC - Form 8-K

### Signatures

Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

OraSure Technologies, Inc.

Date: May 13, 2002

By: /s/ Jack E. Jerrett

-----  
Jack E. Jerrett  
Vice President, General Counsel  
and Secretary

### EXHIBIT INDEX

#### Exhibit

-----

99 Press Release issued May 13, 2002 by the Company announcing receipt of notification from the U.S. Food and Drug Administration that the OraQuick(R) Rapid HIV-1 Antibody Test is approvable, subject to the Company meeting certain conditions.